Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The phase II, randomised study is to explore the efficacy and safety of toripalimab as
consolidation therapy in patients with limited-stage small cell lung cancer who have not
progressed following concurrent chemoradiation therapy
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangzhou Panyu Central Hospital The First Affiliated Hospital of Guangzhou Medical University